Dynamic Advisor Solutions LLC Reduces Holdings in GSK plc (NYSE:GSK)

Dynamic Advisor Solutions LLC lowered its position in GSK plc (NYSE:GSK) by 5.3% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 8,850 shares of the pharmaceutical company’s stock after selling 495 shares during the period. Dynamic Advisor Solutions LLC’s holdings in GSK were worth $299,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. AQR Capital Management LLC lifted its stake in shares of GSK by 103.4% in the second quarter. AQR Capital Management LLC now owns 26,363 shares of the pharmaceutical company’s stock worth $1,015,000 after buying an additional 13,403 shares in the last quarter. Creative Planning lifted its stake in GSK by 4.8% in the 2nd quarter. Creative Planning now owns 203,246 shares of the pharmaceutical company’s stock worth $7,825,000 after purchasing an additional 9,322 shares in the last quarter. NewEdge Advisors LLC boosted its holdings in shares of GSK by 61.9% during the 2nd quarter. NewEdge Advisors LLC now owns 70,048 shares of the pharmaceutical company’s stock worth $2,697,000 after purchasing an additional 26,793 shares during the last quarter. New Wave Wealth Advisors LLC purchased a new stake in shares of GSK in the second quarter valued at approximately $357,000. Finally, Sanctuary Advisors LLC acquired a new stake in shares of GSK in the second quarter valued at approximately $11,181,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

GSK Trading Down 1.1 %

Shares of GSK stock opened at $35.12 on Wednesday. GSK plc has a 1-year low of $31.72 and a 1-year high of $45.92. The firm has a market cap of $72.78 billion, a PE ratio of 22.80, a price-to-earnings-growth ratio of 1.31 and a beta of 0.63. The company has a 50-day moving average of $33.94 and a two-hundred day moving average of $37.78. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on GSK shares. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. StockNews.com downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Finally, Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and dropped their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Six investment analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.